The Appraisal Committee considered evidence submitted by the manufacturer of entecavir and a review of this submission by the Evidence Review Group (ERG). The manufacturer approached the initial ...

A two-year trial of entecavir followed by lamivudine in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24 percent and 12 percent drug-resistance rate.

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

August 25, 2010 — Long-term antiviral therapy for 3 years or more with entecavir reverses fibrosis and cirrhosis in patients with chronic hepatitis B virus (HBV) infection, according to a new study ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of ...

Entecavir has demonstrated safety and efficacy in the treatment of chronic hepatitis B infection. It is the prototype for the cyclopentane class of nucleoside/nucleotide chronic hepatitis B antiviral ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

Please provide your email address to receive an email when new articles are posted on . At 5 years, overall survival rates were 54.2% in the entecavir group vs. 64% in the tenofovir disoproxil group.

Learn everything you need to know about Entecavir-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

The Price section compares costs of the same generic drugs across brands and is purely for information purpose. Medindia neither buys nor sells drugs. Entecavir (Baraclude (1 mg)) is an oral antiviral ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of entecavir for the treatment of chronic hepatitis B, having considered evidence on the nature of the ...